Age-Related Macular Degeneration (AMD)NCT07744984
The Efficacy of Home OCT Supported Management in Patients Diagnosed With Neovascular-AMD and Undergoing a Drug Switch to Faricimab
An observational study of Age-Related Macular Degeneration (AMD) and Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD, run by Rabin Medical Center at 1 site in Israel.
Trial summary
Age-related macular degeneration (AMD) is a common eye disease that can lead to vision loss. The neovascular ("wet") form of AMD is usually treated with repeated injections into the eye. However, some patients do not respond well to their current treatment and need to switch to a different medication. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Age-Related Macular Degeneration (AMD), Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
- What is being tested?
- Home Optical Coherence Tomography (Home OCT)
- Type of treatment
- Medical device
- How many people
- 12 participants
- Where
- 1 siteIsrael
- Study dates
- 3 Jul 2024to 1 Jul 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study will include up to 20 patients diagnosed with nvAMD who received at least 3 consecutive anti VEGF injections without showing a treatment response, as confirmed by a retina specialist, and who are being transitioned to treatment with Faricimab per the discretion of their treating retina specialist. All patients in the study will sign a consent form.
Who may be able to join
- Patients at least 55 years of age.
- Visual Acuity of 20/320 or better in the study eye.
- Diagnosis of active nvAMD that was treated with at least 3 consecutive anti-VEGF injections.
- Patients are meeting the standard care criteria to switch to a second line drug.
- Patients are able and willing to conduct daily OCT self-imaging at home for the duration of the study.
- Patient signing a consent form
Who cannot join
- Patients with any other retinal disease in the study eye requiring steroidal or anti-VEGF injections (anti-VEGF injections during the study period must be for nvAMD).
- Any concurrent ocular condition precluding acquisition of OCT images (eg, severe blepharoptosis, corneal opacification, cataract etc) in the study eye
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Home OCT-Guided Management of Neovascular Age Related Macular Degeneration: Outcomes and Insight After Switch to Faricimab for One Year
Age-related macular degeneration (AMD) is a common eye disease that can lead to vision loss. The neovascular ("wet") form of AMD is usually treated with repeated injections into the eye. However, some patients do not respond well to their current treatment and need to switch to a different medication.
The purpose of this study is to evaluate whether using a home optical coherence tomography (Home OCT) device can improve the management of patients with neovascular AMD who are switching to faricimab treatment after an insufficient response to previous therapy. The Home OCT device allows participants to perform retinal scans at home several times a week. These scans are securely transmitted to the study team, allowing physicians to monitor changes in the retina more frequently than with routine clinic visits alone.
Read more
Participants will continue to receive the standard medical care determined by their treating retina specialist, including clinic visits, eye examinations, retinal imaging, and intravitreal injections. The Home OCT device will provide additional information to help detect changes in disease activity between clinic visits. If the scans suggest worsening of the condition, participants may be asked to return for an earlier evaluation.
The study aims to determine whether frequent home monitoring can identify treatment response sooner and support more personalized treatment decisions. The study will also collect information on the effectiveness of faricimab in routine clinical practice after switching from previous anti-VEGF therapy.
- Conditions
- Age-Related Macular Degeneration (AMD), Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
- Being tested
- Home Optical Coherence Tomography (Home OCT)
- Keywords
- Neovascular AMD, Wet AMD, Home OCT, Optical Coherence Tomography, Faricimab, Anti-VEGF, Retina, Home Monitoring, Notal Vision
- Medical subject headings
- Macular Degeneration
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Home Optical Coherence Tomography (Home OCT)Device
Also called Notal Vision Home OCT, SCANLY Home OCT
Participants will be provided with a Notal Vision Home OCT device for home retinal imaging. They will perform self-imaging at least four times per week throughout the study. OCT images will be securely transmitted to the study team for remote review, enabling frequent monitoring of retinal fluid and disease activity in addition to routine clinical care
| Study group | Role | What they receive |
|---|---|---|
| Home OCT Monitoring Cohort | Participants with neovascular age-related macular degeneration (nAMD) who are switching to faricimab after an inadequate response to previous anti-VEGF therapy. Participants will receive standard clinical care and perform home retinal monitoring using the Notal Vision Home OCT device at least four times per week for up to 12 months. Home OCT images will be reviewed by the study investigators to support disease monitoring and clinical decision-making. Receives: Device: Home Optical Coherence Tomography (Home OCT) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Measure the efficacy of Home-OCT in the management of nvAMD treated with Faricimab.
Time from the first faricimab injection to successful treatment response, defined by the investigator based on the ability to maintain disease control while extending treatment intervals, as assessed using Home OCT monitoring, clinical examination, and retinal imaging.
Measured: Up to 12 months
Secondary outcomes (2)
Faricimab Injection Interval
Mean interval between consecutive faricimab injections during the study
Measured: Up to 12 months
Number of Faricimab Injections
Total number of faricimab injections administered during the study period.
Measured: Up to 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Aug 2026
- Study start3 Jul 2024
- Primary completion1 Apr 2026
- Study completion1 Jul 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Age-Related Macular Degeneration (AMD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 12 participants (actual)
Sponsor and investigators
- Lead sponsor
- Rabin Medical Center
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Orly Gal-Or, Rabin Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07744984
- Sponsor's protocol ID
- 0337-24-RMC
- Status last verified
- Aug 2026
- First submitted
- 29 Jul 2026
- Last updated
- 1 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Home OCT-Guided Management of Neovascular Age Related Macular Degeneration: Outcomes and Insight After Switch to Faricimab for One Year
- ClinicalTrials.gov ID
- NCT07744984
- Acronym / sponsor ID
- 0337-24-RMC
- Conditions
- Age-Related Macular Degeneration (AMD), Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
- Keywords
- Neovascular AMD, Wet AMD, Home OCT, Optical Coherence Tomography, Faricimab, Anti-VEGF, Retina, Home Monitoring
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 12 participants (actual)
- Lead sponsor
- Rabin Medical CenterUniversity, hospital or other
- Study start
- 3 Jul 2024 (actual)
- Primary completion
- 1 Apr 2026 (actual)
- Study completion
- 1 Jul 2026 (actual)
- First posted
- 4 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Age-related macular degeneration (AMD) is a common eye disease that can lead to vision loss. The neovascular ("wet") form of AMD is usually treated with repeated injections into the eye. However, some patients do not respond well to their current treatment and need to switch to a different medication.
The purpose of this study is to evaluate whether using a home optical coherence tomography (Home OCT) device can improve the management of patients with neovascular AMD who are switching to faricimab treatment after an insufficient response to previous therapy. The Home OCT device allows participants to perform retinal scans at home several times a week. These scans are securely transmitted to the study team, allowing physicians to monitor changes in the retina more frequently than with routine clinic visits alone.
Participants will continue to receive the standard medical care determined by their treating retina specialist, including clinic visits, eye examinations, retinal imaging, and intravitreal injections. The Home OCT device will provide additional information to help detect changes in disease activity between clinic visits. If the scans suggest worsening of the condition, participants may be asked to return for an earlier evaluation.
The study aims to determine whether frequent home monitoring can identify treatment response sooner and support more personalized treatment decisions. The study will also collect information on the effectiveness of faricimab in routine clinical practice after switching from previous anti-VEGF therapy.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Home OCT Monitoring Cohort | – | Device: Home Optical Coherence Tomography (Home OCT)Participants with neovascular age-related macular degeneration (nAMD) who are switching to faricimab after an inadequate response to previous anti-VEGF therapy. Participants will receive standard clinical care and perform home retinal monitoring using the Notal Vision Home OCT device at least four times per week for up to 12 months. Home OCT images will be reviewed by the study investigators to support disease monitoring and clinical decision-making. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study will include up to 20 patients diagnosed with nvAMD who received at least 3 consecutive anti VEGF injections without showing a treatment response, as confirmed by a retina specialist, and who are being transitioned to treatment with Faricimab per the discretion of their treating retina specialist. All patients in the study will sign a consent form.
Key inclusion criteria (6 listed)
- Patients at least 55 years of age.
- Visual Acuity of 20/320 or better in the study eye.
- Diagnosis of active nvAMD that was treated with at least 3 consecutive anti-VEGF injections.
- Patients are meeting the standard care criteria to switch to a second line drug.
- Patients are able and willing to conduct daily OCT self-imaging at home for the duration of the study.
Key exclusion criteria (2 listed)
- Patients with any other retinal disease in the study eye requiring steroidal or anti-VEGF injections (anti-VEGF injections during the study period must be for nvAMD).
- Any concurrent ocular condition precluding acquisition of OCT images (eg, severe blepharoptosis, corneal opacification, cataract etc) in the study eye
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Home Optical Coherence Tomography (Home OCT)Also: Notal Vision Home OCT, SCANLY Home OCTParticipants will be provided with a Notal Vision Home OCT device for home retinal imaging. They will perform self-imaging at least four times per week throughout the study. OCT images will be securely transmitted to the study team for remote review, enabling frequent monitoring of retinal fluid and disease activity in addition to routine clinical care | Device | Home OCT Monitoring Cohort |
Primary outcome
Measure the efficacy of Home-OCT in the management of nvAMD treated with Faricimab.
Time frame: Up to 12 months
Time from the first faricimab injection to successful treatment response, defined by the investigator based on the ability to maintain disease control while extending treatment intervals, as assessed using Home OCT monitoring, clinical examination, and retinal imaging.
2 secondary outcomes
Faricimab Injection Interval
Time frame: Up to 12 months
Number of Faricimab Injections
Time frame: Up to 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Age-Related Macular Degeneration (AMD)
RecruitingPhase 3
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Neovascular Age-related Macular Degeneration
RecruitingObservational study
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration
Age-related Macular Degeneration (AMD)
Active, not recruitingObservational study
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
Active, not recruitingObservational study
Retinal Pigment Epithelium Safety Study For Patients In B4711001
Age Related Macular Degeneration
RecruitingObservational study
National Ophthalmic Genotyping and Phenotyping Network (eyeGENE (Registered Trademark)), Stage 3 - Expansion of DNA and Data Repositories for Rare Inherited Ophthalmic Diseases
Inherited Ophthalmic Diseases, Hypopigmentation Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Age-Related Macular Degeneration (AMD) and Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD, run by Rabin Medical Center at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Measure the efficacy of Home-OCT in the management of nvAMD treated with Faricimab. (time frame: Up to 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Sep 2026.